Silence Therapeutics prices $175 million ADS offering at $13.50 per share
The siRNA drugmaker priced 12,962,963 ADSs on August 11, 2026, with the offering expected to close August 13.
SEC filing (3)
Latest
4 stories
Wednesday, August 12
Monday, August 10
Silence Therapeutics reports positive Phase 2 topline data for divesiran in polycythemia vera
The SANRECO trial hit its primary and secondary endpoints, and Silence plans a Phase 3 study in the first half of 2027.
SEC filing
Silence Therapeutics reports Q2 2026 results and divesiran trial progress
The company finished dosing all patients in the Phase 2 SANRECO trial for divesiran and reported $72.1 million in cash as of June 30, 2026.
SEC filing
Thursday, July 16
Silence Therapeutics discloses separation terms for Craig Tooman in amended 8-K
The company amended a December 2025 filing to detail severance and benefits following Tooman's December 14, 2025 separation.
SEC filing